Topical ocular drug delivery systems: Innovations for an unmet need

Yang, Yingjia; Lockwood, Alastair

doi:10.1016/j.exer.2022.109006

Cited by 31 publications

(25 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditionally, the tear film is described as a three-layered structure—an outer lipid layer produced by the Meibomian glands, a middle aqueous layer, and an inner mucous layer secreted predominantly by the conjunctival goblet cells [ 55 ]. However, a more recent theory considers that the tear film consists of two layers—an outer lipid layer and an inner muco-aqueous, gel-like layer [ 55 , 56 , 57 ]. Regarding ocular delivery, both layers exhibit barrier functions, the lipid one for hydrophilic drugs and the muco-aqueous layer for hydrophobic drugs [ 58 ].…”

Section: Eye Anatomy Barriers and Routes In Ocular Drug Deliverymentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.

show abstract

Section: Eye Anatomy Barriers and Routes In Ocular Drug Deliverymentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Thus, the permanence and bioavailability of drugs administered by conventional eye drops on the eye surface are very low. Typically, less than 5% of the administered dose by classic eye drops can be absorbed by ocular tissues [ 138 , 139 ].…”

Section: Drug Delivery Alternatives For the Lf Topical Administrationmentioning

confidence: 99%

“…Different alternatives based on the improvement of the drug permanence on the ocular surface, drug bioavailability, and penetration into the ocular tissues have been proposed [ 140 ]. Several hydrogel-based ophthalmic formulations, as well as different hydrophobic colloidal systems, have been recently reported as alternatives to improve the drug permanence on the ocular surface, drug absorption into the cornea and controlled drug release [ 138 , 139 ].…”

Section: Drug Delivery Alternatives For the Lf Topical Administrationmentioning

confidence: 99%

Biomedical Applications of Lactoferrin on the Ocular Surface

et al. 2023

View full text Add to dashboard Cite

Lactoferrin (LF) is a first-line defense protein with a pleiotropic functional pattern that includes anti-inflammatory, immunomodulatory, antiviral, antibacterial, and antitumoral properties. Remarkably, this iron-binding glycoprotein promotes iron retention, restricting free radical production and avoiding oxidative damage and inflammation. On the ocular surface, LF is released from corneal epithelial cells and lacrimal glands, representing a significant percentage of the total tear fluid proteins. Due to its multifunctionality, the availability of LF may be limited in several ocular disorders. Consequently, to reinforce the action of this highly beneficial glycoprotein on the ocular surface, LF has been proposed for the treatment of different conditions such as dry eye, keratoconus, conjunctivitis, and viral or bacterial ocular infections, among others. In this review, we outline the structure and the biological functions of LF, its relevant role at the ocular surface, its implication in LF-related ocular surface disorders, and its potential for biomedical applications.

show abstract

“…This product is the world's first and only drug-eluting contact lenses indicated for prevention of ocular itching due to allergic conjunctivitis upon daily application. Additionally, this product is used for vision correction in patients having no red eyes [55].…”

Section: New and Advanced Ocular Drug Delivery Systems 61 Contact Lensesmentioning

confidence: 99%

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

El-Kamel¹,

Ashour²

2023

Advanced Drug Delivery Systems

View full text Add to dashboard Cite

Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers. The emerging nanoscience is playing an important role in the development of novel strategies for ocular disease management. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and interact with certain ocular tissues. In this chapter, highlights will be made on barrier to intraocular delivery, general pathways for ocular absorption, and factors affecting intraocular bioavailability. The recent attempts of nanotechnology for treating anterior and posterior ocular diseases will be explored. This will include nanomicelles, nanoparticles, nanosuspensions, vesicular systems, in situ gel, dendrimers, contact lenses, implants, microneedles, and cell-based delivery systems. In addition, gene-based ocular delivery systems will be discussed. In this chapter, we will also provide a comprehensive overview of drug-device combinations used for ocular diseases such as glaucoma, dry eye disease, infections, and inflammations. Furthermore, drug delivery devices for ocular surgeries are discussed. Finally, challenges and future prospective of ocular delivery systems will be explored.

show abstract

Topical ocular drug delivery systems: Innovations for an unmet need

Cited by 31 publications

References 138 publications

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Biomedical Applications of Lactoferrin on the Ocular Surface

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

Contact Info

Product

Resources

About